GO
Loading...

Sanofi SA

More

  • Sacked Sanofi boss joins PureTech board Friday, 27 Feb 2015 | 10:08 AM ET

    PARIS, Feb 27- Chris Viehbacher, sacked as chief executive of French drugs firm Sanofi last year, is to join the board of PureTech, a privately owned healthcare science and technology R&D company. Viehbacher, who moved to Boston last year while he was still running Sanofi, raised the French company's multinational profile during his six years in the job by...

  • Feb 26- Sanofi's new Toujeo diabetes drug has won U.S. regulatory approval but with wording on its label that analysts say could make marketing difficult. Sanofi shares were 1 percent lower at 88.20 euros by 1029 GMT. Sanofi bought some time with a patent infringement lawsuit filed last year against Eli Lilly and Co to keep a cheaper Lantus generic off the market...

  • Feb 23- Eli Lilly and Co said it would postpone by at least two years the marketing application for its once-daily diabetes treatment to evaluate liver concerns, a delay some analysts said could doom the experimental drug. In the meantime, Lilly continues to develop a cheaper, rival "biosimilar" form of Sanofi's blockbuster once-daily Lantus insulin that...

  • PARIS, Feb 23- French pharmaceuticals group Sanofi came under fire from French government ministers on Monday over a welcome bonus planned for its new CEO. Sanofi's new boss, Olivier Brandicourt could pocket a one-off golden handshake of 4 million euros in addition to making 4.2 million euros a year. Executive pay is frequently a touchy subject in egalitarian...

  • NEW YORK/ FRANKFURT, Feb 20- Warren Buffett's Berkshire Hathaway Inc said on Friday it had agreed to buy German motorcycle apparel and accessories retailer Detlev Louis Motorrad-Vertriebs GmbH for a little more than 400 million euros. The purchase enables Buffett, known for his optimism about the United States and the investment opportunities it offers, to...

  • PARIS, Feb 20- Sanofi's new boss Olivier Brandicourt could earn up to 4.2 million euros a year at the drugs group and pocket an extra 4 million euros within 12 months as a one-off golden handshake. Brandicourt will also get 220,000 stock options and 45,000 performance shares a year in Sanofi, matching Viehbacher's award. He has a higher cash earnings potential...

  • New Sanofi boss will earn up to 4.2 mln eur a year Friday, 20 Feb 2015 | 1:36 PM ET

    PARIS, Feb 20- Sanofi's new boss Olivier Brandicourt will earn up to 4.2 million euros a year at the drugs group and could pocket 4 million extra as a one-off golden handshake. The pay of the former medical doctor, who is due to take up his new role from April, was revealed in a statement by the French drugs firm on Friday, a day after the 59- year-old Bayer AG executive was...

  • PARIS, Feb 19- French drugmaker Sanofi on Thursday named Olivier Brandicourt, a Paris- educated doctor and head of Bayer AG's healthcare arm, as its chief executive officer. Brandicourt had been widely tipped to become Sanofi's new boss, a position that opened when Chris Viehbacher was suddenly sacked last year. "Olivier Brandicourt's strong experience...

  • Sanofi hires Bayer HealthCare's Brandicourt as new CEO Thursday, 19 Feb 2015 | 5:36 PM ET

    NEW YORK— French drugmaker Sanofi says it is hiring Bayer HealthCare Chairman and CEO Olivier Brandicourt as its next CEO. Sanofi said Thursday Brandicourt, 59, will start on April 2. Sanofi's board fired CEO Christopher Viehbacher in October because it was unhappy about his handling of the business, including the loss of U.S. market share for its diabetes drug...

  • Feb 17- CVS Health on Monday warned that costs of a potent new class of cholesterol treatments and other specialty drugs in development could eclipse those of expensive new medicines and overwhelm the healthcare system "if rigid cost control mechanisms are not put in place." CVS' call for cost controls follows sharp criticism from insurers, other payers and...

  • LONDON, Feb 17- Bonds issued by European blue chips such as EDF, Nestle and Royal Dutch Shell have slipped into negative-yield territory as investors seek refuge from sub-zero central bank rates. The European Central Bank's monetary easing measures- including a deposit rate at -0.2 percent and a pledge to buy 1 trillion euros of bonds- have turned bond markets on...

  • From school in the late 1970 s and 1980 s, when only elite students gained entry into China's few biochemistry and molecular biology programs, they left China, graduated and worked their way up to senior positions in the world's top pharmaceutical companies. For decades, China tried to woo them home, but they were reluctant to return to a cloistered, politicized...

  • Feb 10- Regeneron Pharmaceuticals Inc reported better-than-expected fourth-quarter sales, driven by surging demand for its blockbuster eye drug Eylea. The biotechnology company's net profit rose to $110.2 million, or 96 cents per share, in the fourth quarter ended Dec. 31 from $96.8 million, or 86 cents per share, a year earlier. Revenue, including...

  • Feb 10- Regeneron Pharmaceuticals Inc reported a nearly 14 percent jump in quarterly profit, driven by strong demand for its blockbuster eye drug Eylea. The biotechnology company's net profit rose to $110.2 million, or 96 cents per share, in the fourth quarter ended Dec. 31 from $96.8 million, or 86 cents per share, a year earlier. Revenue, including collaboration...

  • Europe shares fall after ECB decision on Greek debt Thursday, 5 Feb 2015 | 3:08 AM ET

    PARIS, Feb 5- European stocks fell early on Thursday after the European Central Bank abruptly canceled its acceptance of Greek bonds in return for funding, shifting the burden onto the country's central bank. The ECB move, which required the support of a majority of central bank chiefs across the euro zone, shows widespread dismay with the new Greek government's...

  • *Weinberg says has stabilized Lantus market share in United States. PARIS, Feb 5- French drugs firm Sanofi said on Thursday it would be in a position to name a new chief executive in the coming weeks as it delivered 1.5 percent quarterly earnings per share growth thanks to the weak euro. "The announcement will be before the end of the first quarter," said Chairman Serge...

  • Weak euro boosts Sanofi earnings, to name CEO in Q1 Thursday, 5 Feb 2015 | 1:33 AM ET

    PARIS, Feb 5- Sanofi said on Thursday it would be in a position to name a new chief executive by the end of the first quarter as it delivered fourth-quarter earnings boosted by the weak euro. The drugs company, which sacked Chris Viehbacher as CEO last year, nevertheless said it would need the euro to stay weak to ensure significant earnings growth this year.

  • CHICAGO, Feb 4- After successfully treating four Ebola patients last year, Emory University in Atlanta is now leading a government-funded project that will use blood from survivors of the deadly virus to test a novel way of treating infectious disease. The Defense Advanced Research Projects Agency, the Pentagon's elite research arm, has awarded Emory up to...

  • Feb 3- Isis Pharmaceuticals Inc's experimental diabetes drug took a longer-than-expected 36 weeks to reduce blood sugar levels in patients with type 2 diabetes. Deutsche Bank's Alethia Young said the data looked less robust that some commonly prescribed treatments and Isis's own experimental glucagon receptor, ISIS-GCGR. Type 2 diabetes is a chronic...

  • Feb 3- Isis Pharmaceuticals Inc said its experimental diabetes drug was effective in reducing the body weight and blood sugar in patients with type 2 diabetes. The drug, ISIS-PTP1B, was tested against a placebo in a mid-stage study comprising 92 type 2 diabetes patients with uncontrolled blood sugar, despite treatment. Type 2 diabetes is a chronic condition...